Ubs Group Ag Brooklyn Immuno Therapeutics, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.23 - $0.71 $1,633 - $5,041	-7,100 Reduced 37.87%	11,646 $3,000
Q2 2022 Aug 10, 2022	BUY	$0.48 - $2.03 $2,518 - $10,649	5,246 Added 38.86%	18,746 $10,000
Q1 2022 May 16, 2022	SELL	$1.76 - $4.84 $5,332 - $14,665	-3,030 Reduced 18.33%	13,500 $28,000
Q4 2021 Feb 14, 2022	BUY	$4.17 - $9.79 $37,429 - $87,875	8,976 Added 118.82%	16,530 $68,000
Q3 2021 Nov 15, 2021	BUY	$8.86 - $17.05 $66,928 - $128,795	7,554 New	7,554 $71,000
Q2 2021 Aug 13, 2021	SELL	$3.75 - $78.5 $2,298 - $48,120	-613 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$3.72 - $12.76 $2,280 - $7,821	613 New	613 $2,000

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.